Xenical OTC Switch Could Require More Actual Use Study, Committees Say
Executive Summary
GlaxoSmithKline, sponsor of the proposed over-the-counter version of the weight loss drug orlistat (Roche's Xenical in the Rx version), could be asked to conduct another actual use trial to support its transition from prescription to OTC status
You may also be interested in...
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed